

ACQUIRED HEMOPHILIA

Paul Giangrande

Oxford Haemophilia Centre and Thrombosis Unit
Oxford, UK

Published by the World Federation of Hemophilia (WFH)

© World Federation of Hemophilia, 2005

The WFH encourages redistribution of its publications for educational purposes by not-for-profit hemophilia organizations. In order to obtain permission to reprint, redistribute, or translate this publication, please contact the Communications Department at the address below.

This publication is accessible from the World Federation of Hemophilia's web site at www.wfh.org. Additional copies are also available from the WFH at:

World Federation of Hemophilia
1425 René Lévesque Boulevard West, Suite 1010
Montréal, Québec H3G 1T7
CANADA
Tel. : (514) 875-7944
Fax : (514) 875-8916
E-mail: wfh@wfh.org
Internet: www.wfh.org

The *Treatment of Hemophilia* series is intended to provide general information on the treatment and management of hemophilia. The World Federation of Hemophilia does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. Dose schedules and other treatment regimes are continually revised and new side-effects recognized. WFH makes no representation, express or implied, that drug doses or other treatment recommendations in this publication are correct. For these reasons it is strongly recommended that individuals seek the advice of a medical adviser and/or to consult printed instructions provided by the pharmaceutical company before administering any of the drugs referred to in this monograph.

Statements and opinions expressed here do not necessarily represent the opinions, policies, or recommendations of the World Federation of Hemophilia, its Executive Committee, or its staff.

Treatment of Hemophilia Monographs
Series Editor
Dr. Sam Schulman

Table of Contents

Summary.....	1
Clinical Features.....	1
Epidemiology.....	2
Laboratory Diagnosis.....	2
Clinical Management.....	3
Postpartum Acquired Hemophilia.....	5
References.....	5
Glossary.....	8

Acquired Hemophilia

Paul Giangrande

Summary

Classical hemophilia is an inherited coagulation disorder due to deficiency of either factor VIII or IX. This is usually associated with bleeding problems from an early age, and bleeding into joints is a typical feature. Acquired hemophilia is a rare condition, and is due to the production of autoantibodies in adult life which inactivate factor VIII. Typical clinical manifestations of the acquired form are extensive cutaneous purpura and internal hemorrhage: bleeding into the joints is not a prominent feature. Both sexes are affected and there may be identifiable underlying conditions. Diagnosis is based on the finding of a low factor VIII level associated with the presence of a time-dependent inhibitor in the plasma. Treatment of the condition involves the use of an activated prothrombin complex concentrate (e.g., FEIBA) or recombinant activated factor VII (NovoSeven) to control bleeding episodes. In addition, immunosuppression with steroids is usually effective at reducing inhibitor production and bringing about a sustained rise in the factor VIII level. Rituximab is a promising new agent in the management of this condition.

Clinical Features

The classical form of hemophilia results in a congenital bleeding tendency associated with a reduction in the factor VIII (or IX) level. Like colour blindness, the inheritance of hemophilia is sex-linked, so males are affected although hemophilia is transmitted by carrier females who do not usually have significant bleeding problems themselves. By contrast, acquired hemophilia is typically a disorder of middle age and occurs equally in both sexes. It is due to the development of autoantibodies directed against factor VIII and the resulting reduction in factor level is associated with a significant bleeding tendency. However, the pattern of bleeding seen in acquired hemophilia is quite distinct from that seen in the more common congenital form. Whereas bleeding into joints (hemarthrosis) is

the hallmark of severe congenital hemophilia, this is unusual in acquired hemophilia where the principal manifestations are bleeding into skin (purpura) and soft tissues. Figures 1 and 2 illustrate typical examples of extensive purpura due to acquired hemophilia.



Figure 1: Extensive purpura over the flanks of a 62-year-old man with acquired hemophilia.




Figure 2: Extensive purpura over the chest and abdomen of a 78-year-old woman with acquired hemophilia.

The reason for the different bleeding pattern in acquired hemophilia remains unknown: there is no demonstrable impairment of platelet function. In a survey of 24 cases treated in a single centre over a 28-year period, purpura and soft tissue hemorrhage were the presenting

problems in the overwhelming majority of 23 cases.[1] Bleeding into soft tissues can worsen rapidly into a compartment syndrome. Other presentations included hematuria (4 cases), gastrointestinal bleeding (2 cases), and prolonged postpartum bleeding (4 cases). This study also emphasized the potential life-threatening nature of the condition as 3 patients (11% of the cohort) died directly of bleeding complications. Other studies have demonstrated a similar mortality in the range of 8-22%, with the highest risk being within the first few weeks after presentation.[2,3,4] It is recognized that there is often an underlying medical condition associated with this autoimmune condition. An association with other autoimmune conditions, malignant disease, certain drugs, and pregnancy has been recognized in various surveys. In approximately half of all cases, there is no obvious underlying cause and the condition is labelled as idiopathic.[2]

Epidemiology

Acquired hemophilia is significantly rarer than the inherited form, affecting around 1-4 per million of the population. As with the conventional inherited form, the condition appears in all ethnic groups and has a worldwide prevalence. It is certainly true to say that the condition is often not recognized or mistaken for other acquired bleeding disorders, such as disseminated intravascular coagulation (DIC). Case presentations within institutions and conferences can help to increase local awareness of the condition among healthcare professionals in other disciplines.

The condition typically presents in middle age and beyond. It rarely arises in childhood, where the presence of an inhibitor on laboratory screening of a previously healthy child is much more likely to represent the presence of a lupus anticoagulant (antiphospholipid antibody). In an analysis of pooled data from 20 surveys encompassing 249 patients, the median age of patients reported with acquired hemophilia was 64 with a range of 8-93 years.[5] In a study from the United Kingdom (population = 58 million), 240 cases were reported in the decade 1985-1996.[6] The age of these patients ranged from 20-99 and only 24 (10%) were less than 50 years old at the time of diagnosis. An underlying

diagnosis, such as cancer or pregnancy, was identified in 98 (41%) of patients in this series.

Laboratory Diagnosis

The typical findings of acquired hemophilia are a prolonged activated partial thromboplastin time (APTT) and a low factor VIII level. The thrombin and prothrombin times are normal, as are both the platelet count and function. Mixing studies can be used to demonstrate the presence of a time-dependent inhibitor of factor VIII. Details of the methodology for the screening of plasma samples for inhibitory antibodies to factor VIII and their quantification can be found in sections 13 and 23 of the WFH laboratory manual, *Diagnosis of Haemophilia and Other Bleeding Disorders*. [7] It is important to distinguish anti-factor VIII inhibitors from the more commonly encountered antiphospholipid antibodies (or "lupus anticoagulant"). In such cases, no correction of the baseline APTT will be seen immediately after mixing test plasma with normal plasma.

The antibodies in acquired hemophilia are invariably directed towards factor VIII and not factor IX. The antibodies are usually polyclonal IgG4 antibodies (rarely IgM or IgA). Most antibodies bind to 44-kD A2 domain and/or 72-kD C2 domain of factor VIII and do not fix complement.

The kinetics of the interaction between factor VIII and the inactivating antibody in acquired hemophilia are unusual, and differ from the usual pattern seen in congenital hemophilia complicated by inhibitor development. The profile shows a non-linear inactivation pattern (type II kinetics), with some residual factor VIII activity identifiable even after incubation at high concentrations of antibody for some time. The lack of complete inactivation of factor VIII even at high concentration is due to the fact that antibodies in acquired hemophilia may react with factor VIII to form a complex with some residual factor VIII activity.[8] What this means in practice is that patients with acquired hemophilia may have measurable factor VIII baseline levels even in the presence of high titer inhibitory antibodies.

Clinical Management

Acquired hemophilia is a rare disorder and the potential for significant bleeding problems is high. It is therefore recommended that such patients be managed in specialist hemostasis units, which have the necessary expertise and blood products available.

It needs to be remembered that many of the patients with this condition are elderly and frail, and they may thus be particularly vulnerable to adverse effects of steroids such as diabetes mellitus, psychosis, osteoporosis, and cataract development. There may well also be ethical issues involved in decisions regarding how far to pursue investigations for underlying pathology and getting truly informed consent, as well as the cost of treatment.[9] At the very least, a thorough medical history should be taken to find out other medical problems and a physical examination with a limited panel of blood tests and radiological examinations to highlight an underlying condition.

Recent medication use should be carefully reviewed as the development of acquired hemophilia has been reported as a very occasional adverse reaction to certain drugs. Drugs that have been implicated in published case reports include antibiotics (such as penicillin and sulphonamides and ciprofloxacin), immune-modifying drugs (interferon, fludarabine), psychotropic drugs (phenytoin, flupentixol, zuclopenthixol) and the antiplatelet agent, clopidogrel. However, this is by no means an exhaustive list and the possibility that any recent drug could have provoked the bleeding disorder must be considered.

The principal products available for the treatment of bleeding episodes are activated prothrombin complex concentrates (such as FEIBA, which contains activated factors VII, IX, and X) or recombinant activated factor VII (NovoSeven). The final choice of product and dose is determined by the site and severity of the bleeding. It should be noted that even extensive cutaneous purpura do not necessarily require treatment.

FEIBA is a plasma-derived concentrate which is subjected to a single viral inactivation with dry

heat vapour treatment.[10] Doses in the range of 50-100 units are given by intravenous infusion, but it is important not to exceed a total of 200 units/kg within a 24-hour period as this may be associated with a risk of venous thromboembolism. A recent retrospective survey of 34 patients with acquired hemophilia documented an overall complete response rate of 86%, with a typical dosage regime of 75 units/kg given every 8-12 hours.[11] The median number of doses required to control a severe bleed was 10 compared to a median of 6 doses for an episode classified as "moderate". There is no easy way to monitor the response to FEIBA in the laboratory and clinical judgement must be relied on.

Recombinant activated factor VII (NovoSeven) is an alternative agent, which has the advantage of freedom from the risk of transmission of blood-borne viruses and other pathogens. An early clinical study of 74 bleeding episodes in 34 patients with acquired hemophilia documented a good response in 75% of bleeding episodes and a partial response in a further 17%.[4] These patients had failed to respond to prior treatment with other blood products, and so the response rate in new patients who have not yet received other products can be expected to be higher. Several smaller studies and case reports have since reinforced the efficacy of this agent in the management of acquired hemophilia. The half-life is relatively short at around 2.5 hours, so frequent dosing may be required. A typical dose regime would be 90-120 micrograms/kg administered every 3 hours until bleeding is controlled. As with FEIBA, laboratory monitoring is not easy. Response to treatment is best assessed on purely clinical grounds although a specific kit for the assay of factor VIIa is commercially available although factor VII assays may also be used to monitor treatment. Shortening of the prothrombin time (PT) will be observed after administration of recombinant activated factor VII.

There are published case reports of arterial thrombosis associated with the use of recombinant activated factor VII, including a case of myocardial infarction specifically in a patient with acquired hemophilia.[12] It is difficult to quantify the risk in the light of such isolated case reports but caution seems

warranted in the treatment of patients with documented cardiovascular risk factors.

Human factor VIII is likely to be very rapidly inactivated by a significant titer of inhibitory antibody and therefore of no practical use, even at high doses. Porcine factor VIII (Hyate: C) was widely used in the past to manage acquired hemophilia.[3] This was based on the rationale that the structure of porcine factor VIII was sufficiently similar to the human form to have some hemostatic effect, but was at the same time sufficiently different to be less susceptible to inactivation by circulating antibodies. This plasma-derived product is no longer available, but a new genetically engineered version is under development and it is quite possible that a recombinant version of porcine factor VIII may soon be available.

Treatment of acquired hemophilia involves two aspects of treatment. Hemostatic agents need to be given to control actual bleeding episodes but some form of immunosuppressive treatment also needs to be given in order to suppress production of the underlying inhibitory antibody. It is recommended that immunosuppressive therapy be initiated as soon as the diagnosis of acquired hemophilia is established. The usual treatment involves administration of prednisolone (prednisone) at a dose of 1 mg/kg combined with cyclophosphamide 50-100 mg/day orally. This regime is based on the results of a randomized clinical trial.[2] Azathioprine may be preferred to the latter in the case of women of child-bearing age. Treatment should be continued for up to six weeks with regular review. Most patients will respond well to such a combination of treatment. However, relapse is not uncommon once the drugs are stopped or the dose reduced. This is potentially problematic as it is not feasible to continue this treatment in the long term. One option is to use periodic pulses of steroid therapy to maintain a satisfactory factor VIII level, but the use of other immunosuppressive agents should also be considered.

It has become clear in recent years that rituximab may be a valuable agent in managing acquired hemophilia. This anti-CD20 monoclonal antibody is primarily used in the management of lymphoma because of its affinity for B lymphocytes. However, it has been

successfully applied in the management of various autoimmune conditions, including autoimmune thrombocytopenia. The usual treatment regime involves four separate intravenous infusions of 375 mg/m² each, administered at weekly intervals. A clinical response is typically seen within a week of the first infusion, with a rise in the factor VIII level and a corresponding fall in the inhibitor titer.[13,14,15,16] It must be remembered that rituximab is not licensed by any of the major regulatory authorities for the treatment of acquired hemophilia and its "off label" use to treat this condition is likely to need prior approval in many institutions. There is now general consensus that the use of rituximab should be considered in cases where patients prove resistant to first line therapy or in patients in whom steroids and/or cytotoxics are best avoided. Some groups now take the view that the use of rituximab should also be considered as initial therapy in cases where the initial antibody titer is high.[17]

Another immunosuppressive agent which has been tried in acquired hemophilia when other treatment does not work is 2-chlorodeoxyadenosine, which was both effective and well tolerated in a small study of just 6 patients who had not been cured by conventional treatment.[18]

Cyclosporin has also been used in several cases,[19,20,21,22] and appears effective particularly when systemic lupus erythematosus is the underlying disorder. Long-term treatment will require appropriate monitoring of plasma levels in order to minimize toxicity, and cyclosporin is contraindicated in renal failure.

Infusions of immunoglobulin may also be helpful. A prospective (non-randomized) trial of immunoglobulin assessed the response to doses of 1 g/day x 2 or 0.4 g x 5 days in 16 patients with acquired hemophilia.[23] The response rate was 30%, with range of response time of 6.5-40 days. A better response was observed in patients with lower initial inhibitor titers (range in patient group was 0.5-1228 BU).

A meta-analysis of 249 cases showed a complete remission rate of 74% after a median follow-up of 12 months.[5] The inhibitor-related mortality rate was 11%. Poor prognostic features

identified in the review were: age at diagnosis (<65 better than ≥ 65 years; achievement of a complete remission (yes better than no); nature of underlying disease (malignant disease worse than others).

Postpartum Acquired Hemophilia

This category deserves special mention as it has some distinct features. Postpartum development of acquired hemophilia is a rare but serious complication of pregnancy. The bleeding tendency is often severe and often requires immediate treatment. However, the prognosis is good and in a review of 51 cases the overall outcome was favourable with 97% survival at two years.[24] Three deaths due to bleeding occurred amongst these patients at 1, 5, and 36 months. This survey showed the highest risk applied after first pregnancy. The median age of the women was 28 years and the average onset of symptoms was two months after delivery. Persistent vaginal bleeding was the most common symptom, reported in 17 of the 51 cases. The antibody titer is often high in postpartum hemophilia and the median inhibitor titer in this series was 20 Bethesda units (BU). The probability of complete remission (CR=absence of the inhibitor and normalization of factor VIII activity) was almost 100% at 30 months. It seems that all postpartum inhibitors will eventually disappear spontaneously over a period of months. Giving a course of immunosuppression hastens recovery by a few months but does not affect the overall response rate. The median time to achieve complete remission for patients who received no treatment was 16 months, compared with 12 months with steroids alone and 8 months with immunosuppression ± steroids. The physician has to decide in individual cases whether the possible beneficial effect of immunosuppressive therapy may outweigh the small but definite risk of this treatment. In view of the length of time it takes for the inhibitor to disappear, the women should be advised to use some form of contraception until remission is achieved.

The limited data available suggest that recurrence of the inhibitor during subsequent pregnancies may occur but is by no means inevitable. A recurrence rate of 0/11 pregnancies

was reported in an early international survey.[25] Data from the Italian registry of acquired hemophilia showed similar results with a recurrence rate of 0/4.[26] The only study to document any cases of recurrence was a survey of centres in North America.[27] Three of 14 women with postpartum acquired hemophilia were documented as having had 6 subsequent pregnancies. There was an anamnestic response during 4 of these and no recurrence in the other 2.

References

1. Yee TT, Taher A, Pasi KJ, Lee CA. A survey of patients with acquired haemophilia in a haemophilia centre over a 28-year period. *Clinical and Laboratory Haematology* 2000; 22(5):275-278.
2. Green D, Lechner K. A survey of 214 non-hemophilic patients with inhibitors to factor VIII. *Thrombosis and Haemostasis* 1981; 45(3):200-203.
3. Morrison AE, Ludlam CA, Kessler C. Use of porcine factor VIII in the treatment of acquired haemophilia. *Blood* 1993; 81(6):1513-1520.
4. Hay CRM, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. *Thrombosis and Haemostasis* 1997; 78(6):1463-1467.
5. Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. *British Journal of Haematology* 2003; 121(1): 21-35.
6. Rizza CR, Spooner RJD, Giangrande PLF on behalf of the UK Haemophilia Centre Doctors' Organisation (UKHCDO). Treatment of haemophilia in the United Kingdom 1981-1996. *Haemophilia* 2001; 7(4):349-359.
7. Kitchen S, and McCraw A, for the WFH Laboratory Sciences Committee. *Diagnosis of Haemophilia and Other Bleeding Disorders*. Montreal, Canada: WFH, 2000. Available in

- printed format in English and Spanish. May also be downloaded free of charge from internet via www.wfh.org.
8. Biggs R, Austen DEG, Denson KWE, Borrett R, Rizza CR. The mode of action of antibodies which destroy factor VIII. II. Antibodies which give complex concentration graphs. *British Journal of Haematology* 1972; 23(2):137-155.
 9. Starr JM. Treating acquired haemophilia: an ethical conundrum. *Age and Ageing* 2001; 30(1):87-88.
 10. Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P, and the members of the French FEIBA study group. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. *Thrombosis and Haemostasis* 2003; 77(6):1113-1119.
 11. Sallah S. Treatment of acquired haemophilia with factor eight inhibitor bypassing activity. *Haemophilia* 2004; 10(2): 169-173.
 12. Guillet B, Pinganaud C, Proulle V, Dreyfus M, Lambert T. Myocardial infarction occurring in a case of acquired haemophilia during the treatment course with recombinant activated VII. *Thrombosis and Haemostasis* 2002; 88(4):698-699.
 13. Kain S, Copeland TS, Leahy MF. Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (rituximab). *British Journal of Haematology* 2002; 119(2):578.
 14. Wiestner A, Cho HJ, Asch AS, Michelis MA, Zeller JA, Peerschke EIB, Weksler BB, Schechter GP. Rituximab in the treatment of acquired factor VIII inhibitors. *Blood* 2002; 100(9):3426-3428.
 15. Jy W, Gagliano-DeCesare T, Kett DH, Horstman LL, Jimenez JJ, Ruiz-Dayao Z et al. Life-threatening bleeding from refractory acquired FVIII inhibitor successfully treated with rituximab. *Acta Hematologica* 2003; 109(4): 206-208.
 16. Stasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. *Blood* 2004; 103(12):4424-4428.
 17. Aggarwal A, Grewal R, Green RJ, Boggio L, Green D, Weksler BB, Wiestner A, Schechter GP. Rituximab for autoimmune haemophilia: a proposed treatment algorithm. *Haemophilia* 2005; 11(1):13-19.
 18. Sallah S, Wan JY. Efficacy of 2-chlorodeoxyadenosine in refractory factor VIII inhibitors in persons without hemophilia. *Blood* 2003; 101(3):943-945.
 19. Schulman S, Langevitz P, Livneh A, Mortinowitz U, Seligsohn U, Varon D. Cyclosporine therapy for acquired factor VIII inhibitor in a patient with systemic lupus erythematosus. *Thrombosis and Haemostasis* 1996; 76(3): 344-346.
 20. Petrovic M, Derom E, Baele G. Cyclosporine treatment of acquired hemophilia due to factor VIII antibodies. *Haematologica* 2000; 85(8):895-896.
 21. Au WY, Lam CCK, Kwong YL. Successful treatment of acquired factor VIII inhibitor with cyclosporin. *Haemophilia* 2004; 10(1):98-100.
 22. Maize JC, Cohen JB. Cyclosporine controls epidermolysis bullosa acquisita co-occurring with acquired factor VIII deficiency. *International Journal of Dermatology* 2005; 44(8):692-694.
 23. Schwartz RS, Gabriel DA, Aledort LM, Green D, Kessler CM. A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin. *Blood* 1995; 86(2):797-804.
 24. Hauser I, Schneider B, Lechner K. Post-partum factor VII inhibitors. A review of the literature with special reference to the value of steroid and immunosuppressive treatment. *Thrombosis and Haemostasis* 1995; 73(1):1-5.

-
25. Coller BS, Hultin MB, Hoyer LW, Miller F, Dobbs JV, Dosik MH, Berger ER. Normal pregnancy in a patient with a prior postpartum factor VIII inhibitor: with observations on pathogenesis and prognosis. *Blood* 1981; 58(3): 619-624.
 26. Baudo F, de Cataldo F for the Italian Association of Haemophilia Centres (AICE). Acquired factor VIII inhibitors in pregnancy: data from the Italian Haemophilia Register relevant to clinical practice. *British Journal of Obstetrics and Gynaecology* 2003; 110(3):311-314.
 27. Solymoss S. Postpartum acquired factor VIII inhibitors: results of a survey. *American Journal of Hematology* 1998; 59(1):1-4.

Glossary

Activated partial thromboplastin time (APPT):

A test that measures blood clotting ability. Taken together with a normal prothrombin time, prolonged APPT is the most useful screening test for detecting deficiencies of factors VIII, IX, XI, and XII.

Activated prothrombin complex concentrate

(APCC): Plasma-derived concentrate that contains many activated clotting factors. These activated clotting factors can bypass certain stages in the coagulation process and are used to treat people with factor VIII or factor IX inhibitors.

Anamnestic response: An immune system mechanism in which the memory of a previous encounter with a foreign substance triggers the formation of antibodies. The rapid increase in inhibitor titer levels as a result of an infusion with clotting factor is one example.

Antibody: A protein produced by the immune system that attacks foreign substances in the body.

Autoantibody: An antibody that attacks a person's own healthy tissue.

Bethesda units (BU): A measurement for the level of an inhibitor in the blood. The BU level indicates the potency of the inhibitor and can be used to determine the effectiveness of factor infusions.

Compartment syndrome: A condition in which increased pressure (caused, for example, from bleeding) in an enclosed area of the body restricts the circulation and can damage nerves, blood vessels, and tissues.

Congenital: Present at birth. It refers to traits or conditions that are inherited or occur during gestation up to the moment of birth.

Cutaneous: Relating to the skin.

Half-life: The time it takes for infused factor to lose half of its potency.

Hematuria: Blood in the urine caused by bleeding in the kidneys or bladder.

Hemorrhage: A general term for bleeding, either internally or on the surface, with significant blood loss. It may be brought on by injury to blood vessels or by a deficiency of certain necessary blood elements such as factor proteins or platelets.

Hemarthrosis: Bleeding into a joint cavity, such as the shoulder, elbow, hip, knee, or ankle.

Idiopathic: Occurring without a known cause.

Inhibitor: Antibodies made by the body to fight off things it sees as foreign which prevent, or inhibit, the functioning of a substance, such as a blood factor protein.

Porcine factor VIII: Factor VIII concentrate made from the blood of pigs, mainly used to treat people with factor VIII inhibitors.

Postpartum: After childbirth.

Prothrombin time (PT): A test that measures blood clotting ability. Prolonged PT may be an indicator of anticoagulants or deficiencies in factors I (fibrinogen), II (prothrombin), V, VII, and X.

Purpura: A condition characterized by bleeding into the skin.

Recombinant: The process of manufacturing proteins using genetic engineering technology. Recombinant proteins are synthetic copies of proteins found in human blood plasma.

Titer: The standard measure of the strength or concentration of a component per volume of a solution.